Most contraceptives not linked to HIV infection, but Depo-Provera may raise risk

Published: 17 August 2016

Birth control pills and some types of injectable and implanted contraceptives were not associated with an increased risk of HIV acquisition in an updated meta-analysis that included several recent studies, researchers reported in the 5 August online edition of AIDS. However, evidence continues to suggest that use of depot medroxyprogesterone acetate (DMPA or Depo-Provera) raises the likelihood of HIV infection. The World Health Organization plans to meet soon to assess whether guidance needs to change in the light of the new findings.

Over the years studies have produced conflicting evidence about the link between hormonal contraception – especially DMPA, a long-acting progesterone-only injectable – and women's risk of HIV infection.

Chelsea Polis of the Guttmacher Institute and colleagues have conducted ongoing systematic reviews and meta-analyses of studies looking at the association between contraception and HIV.

At the 2012 International AIDS Conference, Polis reported that studies to date did not show a link between oral contraceptives and HIV infection after adjusting for confounding, nor did the less widely used progesterone-only injectable norethisterone enantate (NET-EN), but a couple of studies saw a significant association with DMPA.

At the 2014 conference, researchers with FHI 360 reported that an individual participant meta-analysis (analysing pooled data from all participants in multiple studies) yielded similar results, as did another meta-analysis published in the February 2015 issue of The Lancet Infectious Diseases.

For the latest updated meta-analysis, commissioned by the World Health Organization, Polis and her team searched for articles published between January 2014 and January 2016. They identified ten new studies since the last review, five of which they deemed relevant to the primary question about the link between contraceptives and HIV infection.

They again found that "the preponderance of data" for oral contraceptive pills, injectable norethisterone enanthate and levonorgestrel implants "do not suggest an association with HIV acquisition." A suggestion of increased risk with NET-EN seen in the previous review was no longer apparent. They stressed, however, that data for levonorgestrel implants are limited and there are no HIV infection data currently available for etonogestrel implants or for contraceptive patches, rings or hormonal IUDs.

They noted that the new, higher-quality studies on DMPA (or injectables considered together), which previously had mixed results in terms of statistical significance, now had hazard ratios between 1.2 and 1.7, or between a 20 and 70% increase in the risk of HIV acquisition. If the association is causal, the true magnitude of the effect is likely < 1.5, they said.

"While confounding in these observational data cannot be excluded, new information increases concerns about DMPA and HIV acquisition risk in women," the study authors concluded. "Data for other hormonal contraceptive methods, including NET-EN, are largely reassuring."

"This is a critical area of research, given that hormonal contraceptives are highly effective methods for preventing unintended pregnancy and its health risks," Polis stated in a Guttmacher Institute press release. "Many places where HIV rates are high also have high levels of unmet need for contraception, unintended pregnancy, and maternal mortality. It is essential that we understand whether use of any particular hormonal contraceptive method could elevate women’s risk of HIV acquisition."

"While definitively inferring causality with observational studies is challenging, it is worth noting that the methodological quality of studies looking at the association of DMPA use with HIV acquisition in women has improved dramatically over time," she added. "This underscores the need to consider next steps on this issue carefully, in terms of clinical guidelines and further research."

WHO to reassess evidence

The World Health Organization (WHO) periodically reviews the latest data to support its global recommendations on contraceptive use. In 2014 the organisation concluded that the evidence available at that time did not support restrictions on the use of injectable contraceptives, given their ease of use and high level of effectiveness in preventing unwanted pregnancy, which can lead to poor health outcomes and increased mortality for women and children.

In a press release issued in response to the new findings, WHO said it will convene an expert review group later this year to examine the links between the use of various hormonal contraceptive methods and women’s risk of HIV acquisition. The group will assess whether current WHO guidance needs to change in the light of the new data review.

"These new data…do strengthen existing concerns about a possible increase in risk of HIV acquisition in women using injectable DMPA, although the statistical significance of these studies varies and they are observational in nature," the release stated.

To overcome some of the drawbacks of observational studies – which are not always able to control for all differences between groups using various interventions – a research consortium is now conducting a randomised trial to compare the risks of HIV acquisition among women using different contraceptive methods. But the results of this study will not be available for several years.

"WHO is concerned that access to preferred contraceptive methods for women, their partners, and for couples, is maximized, while protecting women’s health and that of their communities," the WHO statement concluded. "Women have the right to the latest and best information and to access their preferred options when choosing a contraceptive method that is safe, effective and acceptable."

Reference

Polis CB et al. Update on hormonal contraceptive methods and risk of HIV acquisition in women: a systematic review of epidemiological evidence, 2016. AIDS. 5 August, 2016 (online ahead of print).

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.